These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 32800588)

  • 1. Reply to: Correspondence on "A new definition for metabolic associated fatty liver disease: an international expert consensus statement": MAFLD: Moving from a concept to practice.
    Eslam M; George J
    J Hepatol; 2020 Nov; 73(5):1268-1269. PubMed ID: 32800588
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to: correspondence regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement": Bringing evidence to the NAFLD-MAFLD debate.
    Eslam M; George J
    J Hepatol; 2020 Dec; 73(6):1575. PubMed ID: 32933781
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement".
    Mak LY; Yuen MF; Seto WK
    J Hepatol; 2020 Dec; 73(6):1573-1574. PubMed ID: 32951910
    [No Abstract]   [Full Text] [Related]  

  • 4. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease.
    Mendez-Sanchez N; Arrese M; Gadano A; Oliveira CP; Fassio E; Arab JP; Chávez-Tapia NC; Dirchwolf M; Torre A; Ridruejo E; Pinchemel-Cotrim H; Castellanos Fernández MI; Uribe M; Girala M; Diaz-Ferrer J; Restrepo JC; Padilla-Machaca M; Dagher L; Gatica M; Olaechea B; Pessôa MG; Silva M
    Lancet Gastroenterol Hepatol; 2021 Jan; 6(1):65-72. PubMed ID: 33181118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What's in a name? Renaming 'NAFLD' to 'MAFLD'.
    Fouad Y; Waked I; Bollipo S; Gomaa A; Ajlouni Y; Attia D
    Liver Int; 2020 Jun; 40(6):1254-1261. PubMed ID: 32301554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa.
    Shiha G; Alswat K; Al Khatry M; Sharara AI; Örmeci N; Waked I; Benazzouz M; Al-Ali F; Hamed AE; Hamoudi W; Attia D; Derbala M; Sharaf-Eldin M; Al-Busafi SA; Zaky S; Bamakhrama K; Ibrahim N; Ajlouni Y; Sabbah M; Salama M; Anushiravani A; Afredj N; Barakat S; Hashim A; Fouad Y; Soliman R
    Lancet Gastroenterol Hepatol; 2021 Jan; 6(1):57-64. PubMed ID: 33181119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAFLD criteria overlooks a number of patients with severe steatosis: Is it clinically relevant?
    Huang J; Kumar R; Wang M; Zhu Y; Lin S
    J Hepatol; 2020 Nov; 73(5):1265-1267. PubMed ID: 32819754
    [No Abstract]   [Full Text] [Related]  

  • 8. The NAFLD-MAFLD debate: Is there a Consensus-on-Consensus methodology?
    Fouad Y; Dufour JF; Zheng MH; Bollipo S; Desalegn H; Grønbaek H; Gish RG
    Liver Int; 2022 Apr; 42(4):742-748. PubMed ID: 35182007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reply to: Correspondence on "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease".
    Xu X; Nan Y
    J Hepatol; 2022 Feb; 76(2):484-485. PubMed ID: 34774637
    [No Abstract]   [Full Text] [Related]  

  • 10. Correspondence: "A multisociety Delphi consensus statement on new fatty liver disease nomenclature".
    Wan KS; Chan WK; Yusoff MFM; Mustapha F; Rifin HM; Ratnam KKY; Ahmad NA
    Ann Hepatol; 2024; 29(4):101485. PubMed ID: 38403072
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
    Lazarus JV; Newsome PN; Francque SM; Kanwal F; Terrault NA; Rinella ME
    Hepatology; 2024 Mar; 79(3):E93-E94. PubMed ID: 37983810
    [No Abstract]   [Full Text] [Related]  

  • 12. [Introduction to the APASL clinical guidelines on the management of metabolic-associated fatty liver disease].
    Shi YW; Xiao QQ; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2020 Nov; 28(11):915-917. PubMed ID: 33256275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redefining fatty liver disease: an international patient perspective.
    Shiha G; Korenjak M; Eskridge W; Casanovas T; Velez-Moller P; Högström S; Richardson B; Munoz C; Sigurðardóttir S; Coulibaly A; Milan M; Bautista F; Leung NWY; Mooney V; Obekpa S; Bech E; Polavarapu N; Hamed AE; Radiani T; Purwanto E; Bright B; Ali M; Dovia CK; McColaugh L; Koulla Y; Dufour JF; Soliman R; Eslam M
    Lancet Gastroenterol Hepatol; 2021 Jan; 6(1):73-79. PubMed ID: 33031758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arabic Association for the Study of Diabetes and Metabolism (AASD) endorsing the MAFLD definition of fatty liver disease.
    Shaltout I; Alkandari H; Fouad Y; Hamed AE
    J Hepatol; 2022 Mar; 76(3):739-740. PubMed ID: 34875311
    [No Abstract]   [Full Text] [Related]  

  • 15. MAFLD: A holistic view to redefining fatty liver disease.
    Eslam M; George J
    J Hepatol; 2021 Apr; 74(4):983-985. PubMed ID: 33453330
    [No Abstract]   [Full Text] [Related]  

  • 16. Metabolic dysfunction-associated fatty liver disease: a new clearer nomenclature with positive diagnostic criteria.
    Lanthier N; Vanuytsel T
    Acta Gastroenterol Belg; 2020; 83(4):513-515. PubMed ID: 33321005
    [No Abstract]   [Full Text] [Related]  

  • 17. NONALCOHOLIC FATTY LIVER DISEASE BRAZILIAN SOCIETY OF HEPATOLOGY CONSENSUS.
    Cotrim HP; Parise ER; Figueiredo-Mendes C; Galizzi-Filho J; Porta G; Oliveira CP
    Arq Gastroenterol; 2016; 53(2):118-22. PubMed ID: 27305420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of mitochondrial function in metabolic dysfunction-associated fatty liver disease using obese mouse models.
    Zhao QY; Ge LH; Zhang K; Chen HF; Zhan XX; Yang Y; Dang QL; Zheng Y; Zhou HB; Lyu JX; Fang HZ
    Zool Res; 2020 Sep; 41(5):539-551. PubMed ID: 32786176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Position statement on the diagnosis and management of non-alcoholic fatty liver disease.
    Alswat KA; Fallatah HI; Al-Judaibi B; Elsiesy HA; Al-Hamoudi WK; Qutub AN; Alturaify N; Al-Osaimi A
    Saudi Med J; 2019 Jun; 40(6):531-540. PubMed ID: 31219486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letter to the Editor: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
    Hoofnagle JH; Doo E
    Hepatology; 2024 Mar; 79(3):E91-E92. PubMed ID: 37983836
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.